Exelixis (EXEL) Retained Earnings (2010 - 2026)
Exelixis (EXEL) posted quarterly Retained Earnings of -$215.8 million for Q2 2026, down 10836.02% year-over-year from N/an in Q2 2025, and down 180.87% quarter-over-quarter from -$76.8 million in Q1 2026.
Analysis
Exelixis (EXEL) Retained Earnings (2010 - 2026) Analysis & Trends
Exelixis' Retained Earnings history runs 17 years deep, the most recent figure standing at -$215.8 million for Q2 2026.
- In Q2 2026, Retained Earnings fell 10836.02% year-over-year to -$215.8 million; the TTM figure through Apr 2026 stood at -$215.8 million (down 10836.02% YoY), while the FY2026 annual figure was -$76.8 million, up 22.12% from the prior year.
- Retained Earnings for Q2 2026 stood at -$215.8 million, down from -$76.8 million in the prior quarter.
- The five-year high for Retained Earnings was $2.6 billion in Q1 2023, with the low at -$258.9 million in Q1 2024.
- The 5-year median for Retained Earnings is $1.3 million (2025), against an average of $815.7 million.
- The sharpest annual moves came in 2023 and 2026: Retained Earnings surged 61486.23% in 2023, then slumped 10836.02% in 2026.
- Exelixis' Retained Earnings stood at -$14.5 million in 2022, then slumped by 1093.8% to -$173.4 million in 2023, then surged by 1462.25% to $2.4 billion in 2024, then sank by 99.85% to $3.6 million in 2025, then sank by 6153.13% to -$215.8 million in 2026.
- Business Quant data shows EXEL's Retained Earnings at -$215.8 million in Q2 2026, -$76.8 million in Q1 2026, and $3.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 2.11 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 2.11 Bn |
| Apr 3, 2026 | 2.15 Bn |
| Jan 2, 2026 | 2.23 Bn |
| Oct 3, 2025 | 2.26 Bn |
| Jul 4, 2025 | 2.25 Bn |
| Apr 4, 2025 | 2.29 Bn |
| Jan 3, 2025 | 2.34 Bn |
| Sep 27, 2024 | 2.36 Bn |
| Jun 28, 2024 | 2.32 Bn |
| Mar 29, 2024 | 2.39 Bn |
| Dec 29, 2023 | 2.44 Bn |
| Sep 29, 2023 | 2.49 Bn |
| Jun 30, 2023 | 2.53 Bn |
| Mar 31, 2023 | 2.56 Bn |
| Dec 30, 2022 | 2.54 Bn |
| Sep 30, 2022 | 2.51 Bn |
| Jul 1, 2022 | 2.48 Bn |
| Apr 1, 2022 | 2.45 Bn |
| Dec 31, 2021 | 2.43 Bn |
| Oct 1, 2021 | 2.42 Bn |